Ann: PTX-100 abstract published online on ASH website, page-9

Not sure if drawing in the SOC and our Target lines will help the interpretation but it should:-




Keeping in mind that this data is from July and not many months on from the last readout in March of this year. The additional data provides two main significances - namely that only one new patient was recruited in that timespan but that all patients in the trial gained another 4 mths on PTX-100 since between the two readouts. Interesting to see that one of the patients previously on the highest dose seems to now be on the lowest and deriving stable disease.